Abstract:Background: Ciprofloxacin is usually used in the treatment of lower respiratory tract infections (LRTIs). Recent studies abroad have shown ciprofloxacin is inadequately dosed and might lead to worse outcomes. The aim of this study was to perform pharmacokinetic and pharmacodynamic analyses of ciprofloxacin in elderly Chinese patients with severe LRTIs caused by Gramnegative bacteria. Methods: From September 2012 to June 2014, as many as 33 patients were empirically administered beta-lactam and ciprofloxacin combination therapy. Patients were in fused with 200 or 400 mg of ciprofloxacin every 12 h, which was determined empirically by the attending physician based on the severity of the LRTI and the patient's renal condition. Ciprofloxacin serum concentrations were determined by high-performance liquid chromatography. Bacterial culture was performed from sputum samples and/or endotracheal aspirates, and the minimum inhibitory concentrations (MICs) of ciprofloxacin were determined. The ratios of the area under the serum concentration-time curve to the MIC (AUC/MIC) and of the maximum serum concentration of the drug to the MIC (C-max/MIC) were calculated. The baseline data and pharmacokinetic parameters were compared between clinical success group and clinical failure group, bacteriologic success group and bacteriologic failure group. Results: Among the 33 patients enrolled in the study, 17 were infected with Pseudomonas aeruginosa, 14 were infected with Acinetobacter baumannii, and two were infected with Klebsiella pneumoniae. The mean age of the patients was 76.9 +/- 6.7 years. Thirty-one patients (93.4%) did not reach the target AUC/MIC value of >125, and 29 patients (87.9%) did not reach the target C-max/MIC value of >8. The AUC/MIC and C-max/MIC ratios in the clinical success group were significantly higher than those in the clinical failure group (61.1 [31.7-214.9] vs. 10.4 [3.8-66.1], Z= -4.157; 9.6 [4.2-17.8] vs. 1.3 [0.4-4.7], Z= -4.018; both P< 0.001). The AUC/MIC and C-max/MIC ratios in the patients for whom the pathogens were eradicated were significantly higher than those in the patients without the pathogens eradicated (75.3 [31.7-214.9] vs. 10.5 [3.8-66.1], Z. 3.938; 11.4 [4.2-17.8] vs. 1.4 [0.4-5.4], Z.-3.793; P < 0.001 for both). Receiver operating characteristic curve analysis showed that the AUC/MIC and C-max/MIC values were closely associated with clinical and bacteriologic efficacies (P < 0.001 in both). Conclusions: Ciprofloxacin is inadequately dosed against Gram-negative bacteria, especially for those with relatively high MIC values. Consequently, the target values, AUC/MIC > 125 and C-max/MIC > 8, cannot be reached.

Efficacy and adverse reactions of homemade pazufloxacin and levofloxacin for treating bacterial infections of the respiratory and urinary systems: a meta-analysis

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Meta-analysis of High-dose and Routine-dose of Levofloxacin in the Treatment of Respiratory Tract Infection

Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis

The Therapeutic Effect of Pazufloxacin Mesilate on Acute Respiratory Infection of the Elderly

Effect of mercifloxacin and levofloxacin on urinary tract infection

Multi-center Clinical Studies on Pazufloxacin Sodium Chloride Injection in Treatment for Acute Bacterial Infections

A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients

Randomized Controlled Clinical Trial of Moxifloxacin Versus Levofloxacin Injection in the Treatment of Community Acquired Pneumonia

The clinical efficacy and safety evaluation of cefazolin sodium combined with levofloxacin for acute urinary tract infection

Safety and Efficacy of Levofloxacin Versus Ciprofloxacin for the Treatment of Chronic Bacterial Prostatitis in Chinese Patients

A randomized multicenter clinical study of injectable levofloxacin in the treatment of acute bacterial infections

Clinical Study of Inhaled Ambroxol in the Adjunctive Treatment of Lower Respiratory Tract Infection Induced by Pseudomonas Aeruginosa

[Adverse Drug Reaction and Rational Use of Levofloxacin: a Prospective Study].

Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims database

Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.

A Randomized Controlled Clinical Study on Levofloxacin Versus Ciprofloxacin in the Treatment of Bacterial Infections

A Multi-Center, Randomized, Controlled, Double Blind and Double Dummy Clinical Trial of Antofloxacin Hydrochloride Tablet Versus Levofloxacin Tablet for the Treatment of Acute Bacterial Infections

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections

Phamacodynamics and pharmacokinetics of levofloxacin in patients with lower respiratory tract infection

Letter to the Editor for the Article “antibiotics Efficacy in Clinical and Microbiological Cure of Uncomplicated Urinary Tract Infection: a Systematic Review and Network Meta-Analysis”